Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ARCT 
Arcturus Therapeutics Holdings Inc (ARCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/15/2025: ARCT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.5
1 Year Target Price $35.5
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 211.96M USD | Price to earnings Ratio - | 1Y Target Price 35.5 |
Price to earnings Ratio - | 1Y Target Price 35.5 | ||
Volume (30-day avg) 11 | Beta 2.1 | 52 Weeks Range 5.85 - 24.17 | Updated Date 12/14/2025 |
52 Weeks Range 5.85 - 24.17 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -68.35% | Operating Margin (TTM) -96.27% |
Management Effectiveness
Return on Assets (TTM) -15% | Return on Equity (TTM) -27.43% |
Valuation
Trailing PE - | Forward PE 2.48 | Enterprise Value 57584526 | Price to Sales(TTM) 2.17 |
Enterprise Value 57584526 | Price to Sales(TTM) 2.17 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA -25.67 | Shares Outstanding 28412537 | Shares Floating 26275346 |
Shares Outstanding 28412537 | Shares Floating 26275346 | ||
Percent Insiders 7.53 | Percent Institutions 86.24 |
About Arcturus Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-04-16 | Founder, President, CEO & Director Mr. Joseph E. Payne M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 174 | Website https://arcturusrx.com |
Full time employees 174 | Website https://arcturusrx.com | ||
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.